대한임상검사과학회지 (Korean Journal of Clinical Laboratory Science)

  • 제50권4호
  • /
  • Pages.462-469
  • /
  • 2018
  • /
  • 1738-3544(pISSN)
  • /
  • 2288-1662(eISSN)
대한임상검사과학회 (Korean Society for Clinical Laboratory Science)
권호 표지
DOI QR코드

DOI QR Code

Geldanamycin과 17-AAG가 구강편평세포암종 세포주에 미치는 암예방 효과

Cancer Chemoprevention Effects of Geldanamycin and 17-AAG in Human Oral Squamous Cell Carcinoma

  • 이은주 (대전보건대학교 임상병리과)
  • Lee, Eun Ju (Department of Clinical Laboratory Science, Daejeon Health Science College)
  • 투고 : 2018.08.16
  • 심사 : 2018.09.13
  • 발행 : 2018.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

HSP90은 세포성장, 분화, 생존에 관련된 다양한 단백질들의 안정화 및 활성조절을 담당 한다. HSP90은 구강을 포함하는 두 경부에 발생하는 편평세포암종의 발생과정에서 점진적으로 증가하는 경향을 나타낸다. 따라서 HSP90 의 발현을 억제함으로서 암을 치료하고자하는 연구가 많이 진행되고 있다. 본 연구에서는 인간의 구강 편평세포암종세포에서 증식과 세포주기에 대한 HSP90 억제제의 효과를 조사하기 위해 구강암 세포주를 대상으로 세포의 생존능 측정, 세포주기분석, 전기영동 분석을 시행하였다. HSP90 억제제 처리 후 세포 증식은 억제되었으며 통계적으로 유효한 성장억제 효과를 나타났고, YD-10B세포와 YD-38세포에 Geldanamycin과 17-AAG를 0, 0.1, 0.3, 1, $10{\mu}M$ 농도로 24 hr 처리한 결과 YD-38에 비해 YD-10B세포가 세포 성장이 현저하게 감소하는 것을 확인하였다. 그 후, 유세포 분석기로 확인해 본 결과 G2 arrest가 관찰되었다. 이상의 연구결과에서 구강암 세포주 YD-10B 세포와 YD-38 세포에서 Geldanamycin은 G2 arrest를 유도하고, $p-GSK-3{\beta}$ pathway를 통하여 세포증식을 억제하여 세포생존을 막는다는 것을 확인하였다. 이를 통해 HSP90 저해제를 이용하여 다양한 암세포주에서 치료 효과를 기대 할 수 있다고 사료된다.

HSP90 regulates various proteins involved in differentiation and cell survival. Levels of HSP90 tend to increase during development of squamous cell carcinoma in the head and neck including the mouth. Thus, many studies have been conducted to treat these cancers through suppression of HSP90. This study investigated the effect of two HSP90 inhibitors, geldanamycin and 17-AAG, on the proliferation, apoptosis, and invasion of human oral squamous cell carcinoma cells. Cell survival and cell cycle analyses, as well as western blot analysis, were performed with oral cancer cell lines, YD-10B and YD-38. After treatment with HSP90 inhibitors, cell proliferation was significantly inhibited. When YD-10B and YD-38 cells were treated with various concentrations of geldanamycin and 17-AAG (0, 0.1, 0.3, 1 and $10{\mu}M$) for 24 hr, the growth of YD-10B cells was markedly reduced compared to that of YD-38 cells. Thereafter, the cells were subjected to flow cytometry, which revealed G2 arrest. These results demonstrated that geldanamycin induced G2 arrest and inhibited cell proliferation through the $p-GSK-3{\beta}$ pathway in YD-10B and YD-38 cells, thus inhibiting cell survival. HSP90 inhibitors are therefore expected to have a therapeutic effect on various cancer cell lines.

키워드

참고문헌

  1. Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011;105:628-639. https://doi.org/10.1038/bjc.2011.240.
  2. Dillon MT, Harrington KJ. Human papillomavirus-negative pharyngeal cancer. J Clin Oncol. 2015;33:3251-61. https://doi.org/10.1200/JCO.2015.60.7804.
  3. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537-549. https://doi.org/10.1038/nrc2887.
  4. Pearl LH, Prodromou C. Structure, function, and mechanism of the HSP90 molecular chaperone. Adv Protein Chem. 2001; 59:157-186. https://doi.org/10.1016/S0065-3233(01) 59005-1.
  5. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761-772. https://doi.org/10.1038/nrc1716.
  6. Neckers L. Chaperoning oncogenes: HSP90 as a target of geldanamycin. Handb Exp Pharmacol. 2006;172:259-277. https://doi.org/10.1007/3-540-29717-0_11.
  7. Pacey S, Banerji U, Judson I, Workman P. HSP90 inhibitors in the clinic. Handb Exp Pharmacol. 2006;172:331-358. https://doi.org/10.1007/3-540-29717-0_14.
  8. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-HSP90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem. 1995;270:24585-24588. https://doi.org/10.1074/jbc.270.41.24585.
  9. Lee EJ, Kim J, Lee SA, Kim EJ, Chun YC, Ryu MH, et al. Characterization of newly established oral cancer cell lines derived from six squamous cell carcinoma and two mucoepidermoid carcinoma cells. Exp Mol Med. 2005;37:379-390. https://doi.org/10.1038/emm.2005.48.
  10. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med. 2001:344:1323-1326. https://doi.org/10.1056/NEJM200104263441710.
  11. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A. 2002;99:12847-12852. https://doi.org/10.1073/pnas.202365899.
  12. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem. 2003;278:13829-13837. https://doi.org/10.1074/jbc.m209640200.
  13. Machida H, Matsumoto Y, Shirai M, Kubota N. Geldanamycin, an inhibitor of HSP90, sensitizes human tumour cells to radiation. Int J Radiat Biol. 2003;79:973-980. https://doi.org/10.1080/09553000310001626135.
  14. Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, Kubota N, et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun. 2006;351:658-663. https://doi.org/10.1016/j.bbrc.2006.10.094.
  15. Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, et al. HSP90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors. Oncol Rep. 2015;33:1499-1504. https://doi.org/10.3892/or.2015.3735.
  16. Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, et al. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 2014;5:2678-2687. https://doi.org/10.18632/oncotarget.1929.
  17. Roh J-L, Kim EH, Park HB, Park JY. The HSP90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53- mediated apoptosis in head and neck cancer. Cell Death Dis. 2013;4:e956. https://doi.org/10.1038/cddis.2013.488.
  18. Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. Low-dose HSP90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 2011;10:4291-4299. https://doi.org/10.4161/cc.10.24.18616.
  19. Barker HE, Patel R, McLaughlin M, Schick U, Zaidi S, Nutting CM, et al. CHK1 inhibition radiosensitises head and neck cancers to paclitaxel-based chemoradiotherapy. Mol Cancer Ther. 2016;15:2042-2054. https://doi.org/10.1158/1535-7163.mct-15-0998.
  20. Friedman JA, Wise SC, Hu M, Gouveia C, Vander Broek R, et al. HSP90 inhibitor SNX5422/2112 targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell carcinoma. Transl Oncol. 2013;6:429-441. https://doi.org/10.1593/tlo.13292.
  21. Suhane T, Laskar S, Advani S, Roy N, Varunan S, Bhattacharyya D, et al. Both the charged linker region and ATPase domain of HSP90 are essential for rad51-dependent DNA repair. Eukaryot Cell. 2015;14:64-77. https://doi.org/10.1128/ec.00159-14.
  22. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel HSP90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer. 2010;126:1216-1225. https://doi.org/10.1002/ijc.24815.
  23. Stingl L, Stuhmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer. 2010;102:1578-91. https://doi.org/10.1038/sj.bjc.6605683.
  24. Wenjie L, Weilin A, Tony T, Anna R, Gabriela C. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener. 2010;5:24. https://doi.org/10.1186/1750-1326-5-24.
  25. Dillon MT, Good JS, Harrington KJ. Selective targeting of the G2/M cell cycle checkpoint to improve the therapeutic index of radiotherapy. Clin Oncol (R Coll Radiol). 2014;26:257-265. https://doi.org/10.1016/j.clon.2014.01.009.
  26. Zhang C-Z, Spektor A, Cornils H, Francis JM, Jackson EK, Liu S, et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015;522:179-184. https://doi.org/10.1038/nature14493.
  27. Wang DH, Zhang YJ, Zhang SB, Liu H, Liu L, Liu FL, et al. Geldanamycin mediates the apoptosis of gastric carcinoma cells through inhibition of EphA2 protein expression. Oncol Rep. 2014;32:2429-2436. https://doi.org/10.3892/or.2014.3542.
  28. Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H. P53-dependent radiosensitizing effects of HSP90 inhibitor 17-Allylamino-17-demethoxy geldanamycin on human oral squamous cell carcinoma cell lines. Int J Oncol. 2006;29:1111-1117. https://doi.org/10.3892/ijo.29.5.1111.

피인용 문헌

  1. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks vol.715, pp.None, 2022, https://doi.org/10.1016/j.abb.2021.109085